Sarepta Therapeutics Inc (NASDAQ:SRPT) Director Hans Lennart Rudolf Wigzell sold 6,667 shares of the firm’s stock in a transaction that occurred on Thursday, November 1st. The stock was sold at an average price of $140.50, for a total transaction of $936,713.50. Following the transaction, the director now directly owns 126,534 shares in the company, valued at $17,778,027. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Shares of SRPT stock opened at $145.97 on Monday. The company has a market cap of $9.75 billion, a P/E ratio of -89.01 and a beta of 1.59. The company has a debt-to-equity ratio of 0.65, a quick ratio of 9.89 and a current ratio of 8.85. Sarepta Therapeutics Inc has a 52-week low of $50.51 and a 52-week high of $176.50.
Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Wednesday, October 24th. The biotechnology company reported ($1.15) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.86) by ($0.29). The business had revenue of $78.49 million for the quarter, compared to analysts’ expectations of $78.84 million. Sarepta Therapeutics had a negative net margin of 89.46% and a negative return on equity of 23.67%. Sell-side analysts anticipate that Sarepta Therapeutics Inc will post -4.38 earnings per share for the current fiscal year.
Hedge funds have recently modified their holdings of the stock. Clarus Wealth Advisors purchased a new position in Sarepta Therapeutics in the second quarter worth $124,000. First Quadrant L P CA purchased a new position in Sarepta Therapeutics in the third quarter worth $130,000. Rockefeller Capital Management L.P. purchased a new position in Sarepta Therapeutics in the second quarter worth $162,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors purchased a new position in Sarepta Therapeutics in the second quarter worth $185,000. Finally, Keybank National Association OH purchased a new position in Sarepta Therapeutics in the second quarter worth $206,000. 89.57% of the stock is currently owned by institutional investors.
A number of equities analysts have recently commented on the stock. BidaskClub lowered shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, October 31st. Piper Jaffray Companies reduced their target price on shares of Sarepta Therapeutics from $189.00 to $168.00 and set an “overweight” rating on the stock in a research report on Friday, October 26th. Zacks Investment Research raised shares of Sarepta Therapeutics from a “hold” rating to a “buy” rating and set a $147.00 target price on the stock in a research report on Tuesday, October 16th. Sanford C. Bernstein assumed coverage on shares of Sarepta Therapeutics in a research report on Friday, October 12th. They set an “outperform” rating and a $170.00 target price on the stock. Finally, Credit Suisse Group raised their target price on shares of Sarepta Therapeutics from $178.00 to $189.00 in a research report on Thursday, October 4th. Three research analysts have rated the stock with a hold rating, twenty-four have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $168.37.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.
Read More: How to Calculate Compound Annual Growth Rate (CAGR)
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.